摘要
急性骨髓性白血病(AML)是成年人常见的急性白血病类型,严重危害健康。Idasanutlin是首个强效的口服双微体2蛋白抑制药,能激活p53通路,诱导癌细胞凋亡。目前的临床前研究和临床试验已经充分证实了其有效性和安全性;与其他的抗癌药合用,也呈现极好的协同作用,是治疗AML的良药,有希望不久获批上市。
Acute myelocytic leukemia （AML） is a common acute leukemia mainly attacking adults. Idasanutlin is an oral, potent and selective small-molecule antagonist with highly binding affinity to MDM2 protein, and its efficacy has been further demonstrated in preclinical studies and clinical trials. In the combination with different anticancer drugs, it showed synergism in cancer cellular lines, therefore, it is potentially used to treat AML in clinics.
出处
《中国药师》
CAS
2018年第9期1645-1647,共3页
China Pharmacist
